Analysis and data insight - Articles - Page 201

COVID-19 market impact illustration: coronavirus, currency symbols, line graph

Global spread of coronavirus puts financial markets into a tailspin

March 3, 2020

Concerns about the escalating global spread of COVID-19 panicked the markets big time at the close of the month. With investors rushing to the sidelines, it only took five days for the Dow Jones Industrial Average to drop more than 10% from its all-time high, getting close to the 30,000 mark.

Biocom Global Life Sciences Partnering Conference

Pharmas share their needs, wants and offer some advice

March 2, 2020

By Brian Orelli

SAN DIEGO – At the Biocom 10th Annual Global Life Sciences Partnering Conference, panels of pharma executives highlighted what they're looking for to supplement their pipelines and offered advice that ran the gamut from company formation to the courting process to strategies for partnering pipeline drugs and platforms.

Week in review for Feb. 24-28, 2020: Two migraine therapies approved

March 2, 2020

By Peter Winter

A quick look back at top stories, including: 1st Biotherapeutics, Acacia, Apeiron, Ascletis, Axovant, Bicycle, Biogen, Biohaven, Boehringer Ingelheim, Cocrystal, Curis, Glaxosmithkline, H. Lundbeck, Makscientific, MPM, NGM, Oramed, Pvp, Redhill, Roche, Sangamo, Shenzhen Xtalpi, Sichuan Clover, Steba, Takeda, Tetra, Tonix, Trutino, Twoxar, Vir, Wuxi.

Biopharma money raised: Jan. 1-Feb. 27, 2020

Feb. 28, 2020

Year-to-date money raised in public, private and other financings of biopharma companies.

Money raised by biopharma: 2020 vs. 2019

Feb. 28, 2020

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Collaborations between biopharmaceutical companies and government/nonprofit entities: January 2020

Feb. 28, 2020

Deals between biopharma companies and government or nonprofit entities, including: Actinium, Angiogenex, Axovant, Bellicum, Bicycle, Canonic, Celgene, Chongqing Zhifei, Cytovia, Decibel, Dinaqor, Diomics, Eagle, Ervaxx, G1, Gene Techno, Genentech, Genethon, Gilead, GSK, Horizon, Hoth, Medigene, Microcures, Moderna, Novartis, Oncotartis, Onxeo, Opiant, Orion, Sapphire, Tacitus, Titan, Valneva, Yposkesi, Zyus.

Deal handshake and arrows sketch on chalkboard

Collaborations between biopharmaceutical companies and government/nonprofit entities: February 2020

Feb. 28, 2020

Deals between biopharma companies and government or nonprofit entities, including: AB Biotics, ACT Genomics, Advent, Agex, Be Cool, Benevolentai, Beroni, Biomarin, Bridge, Chugai, CNS, Cocrystal, Dianomi, Enochian, Entourage Phytolab, Erytech, Evgen, Exicure, Genprex, Gibson Oncology, GSK, J&J, Novartis, Oncologie, Orgenesis, Sanofi Pasteur, Sapphire, Synspira, Theratechnologies, Toa Eiyo, VBL, WPD.